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AbstrAct
Introduction Retrievable inferior vena cava (IVC) filters 
have been increasingly used in patients with major trauma 
who have contraindications to anticoagulant prophylaxis 
as a primary prophylactic measure against venous 
thromboembolism (VTE). The benefits, risks and cost-
effectiveness of such strategy are uncertain.
Methods and analysis Patients with major trauma, 
defined by an estimated Injury Severity Score >15, who 
have contraindications to anticoagulant VTE prophylaxis 
within 72 hours of hospitalisation to the study centre will 
be eligible for this randomised multicentre controlled 
trial. After obtaining consent from patients, or the persons 
responsible for the patients, study patients are randomly 
allocated to either control or IVC filter, within 72 hours 
of trauma admission, in a 1:1 ratio by permuted blocks 
stratified by study centre. The primary outcomes are (1) 
the composite endpoint of (A) pulmonary embolism (PE) 
as demonstrated by CT pulmonary angiography, high 
probability ventilation/perfusion scan, transoesophageal 
echocardiography (by showing clots within pulmonary 
arterial trunk), pulmonary angiography or postmortem 
examination during the same hospitalisation or 90-day 
after trauma whichever is earlier and (B) hospital mortality; 
and (2) the total cost of treatment including the costs of 
an IVC filter, total number of CT and ultrasound scans 
required, length of intensive care unit and hospital stay, 
procedures and drugs required to treat PE or complications 
related to the IVC filters. The study started in June 2015 
and the final enrolment target is 240 patients. No interim 
analysis is planned; incidence of fatal PE is used as safety 
stopping rule for the trial.
Ethics and dissemination Ethics approval was 
obtained in all four participating centres in Australia. 
Results of the main trial and each of the secondary 
endpoints will be submitted for publication in a peer-
reviewed journal.
Trial registration number ACTRN12614000963628; Pre-
results.
IntroductIon
Venous thromboembolism (VTE), including 
deep vein thrombosis (DVT) and pulmonary 
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Protocol
Strengths and limitations of this study
 ► This study is conducted as a phase IIb multicentre 
randomised controlled trial (RCT) concerning the 
benefits and risks of early use of inferior vena 
cava (IVC) filters in patients with major trauma who 
have contraindications to anticoagulant prophylaxis 
against venous thromboembolism (VTE). It will 
provide the much needed important information 
to clinicians about the best strategy to reduce the 
burden of VTE in patients with major trauma.
 ► In addition to clinical effectiveness, this study will 
also examine the (A) mechanical complications 
of IVC filters, (B) bleeding complications, (C) cost-
effectiveness and (D) long-term health outcomes 
after using IVC filters as a primary VTE prophylactic 
measure in patients with major trauma.
 ► Blinding of the treating clinicians to treatment 
allocation is deemed to be impossible; centralised 
web-based randomisation to ensure adequate 
allocation concealment, and strict guidelines on 
when and how often a CT pulmonary angiography 
(CTPA) should be performed to detect mild or early 
pulmonary embolism for the study patients. This 
study design will (A) reduce outcome detection bias, 
(B) avoid unnecessary radiation from routine CTPA 
for asymptomatic study patients and (C) ensure the 
clinical safety of the patient allocated to the control 
group.
 ► The study is not powered to detect a small to 
moderate difference in 90-day mortality (<9%); but 
the results of this study will inform us whether a 
phase III RCT is necessary to confirm the role of IVC 
filters—as a primary VTE prophylactic device—for 
patients with major trauma.
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embolism (PE), is one of the most preventable causes 
of death and morbidity in hospitalised patients.1 2 VTE 
accounted for over 14 000 hospitalisations (or 70 per 
100 000) and 5000 deaths in Australia in 20083; and 
according to the New South Wales Clinical Excellence 
Commission, a large number of hospital-associated VTE 
(n=2229) including fatal PE were identified in 2012 
and 2013. The total cost of VTE per person per annum, 
including loss in productivity, was estimated to be over 
US$1.47 million and the total cost of VTE for Australia 
in 2008 was $A3.9 billion.3 The total burden of VTE in 
the European Union countries exceeded 1.6 million 
events, comprising 0.7 million cases of DVT, 0.4 million 
cases of non-fatal PE and 0.5 million VTE-related deaths.4 
The majority of patients with VTE-related deaths were 
untreated with VTE prophylaxis and VTE was not diag-
nosed before postmortem; only 7% of deaths occurred 
in those on prophylaxis or therapy.5 Studies of routine 
screening of hospital patients for asymptomatic DVT 
have shown that VTE is common but clinically silent in 
a high proportion. As such, VTE prophylaxis is of para-
mount importance in reducing mortality and morbidity 
of VTE. Although underutilisation of VTE prophylaxis in 
many situations has improved with education and use of 
electronic prescription alert systems, recent studies show 
that a significant proportion of hospitalised patients, at 
high risk for VTE, including those who are critically ill or 
injured, do not receive VTE prophylaxis.6 7
The incidence of asymptomatic VTE, including PE, in 
critically ill or injured patients is very high despite anti-
coagulant prophylaxis.8 In one cohort study, up to 10% 
of the patients already had unsuspected DVT at the time 
of intensive care unit (ICU) admission.9 The American 
College of Chest Physicians guidelines recommend that 
all ICU patients should be assessed for their risk of VTE, 
and that most should receive VTE prophylaxis on admis-
sion to the ICU.10 Both the National Quality Forum and 
The Joint Commission (the organisation that accredits 
American hospitals) also recommend that the proportion 
of patients who receive VTE prophylaxis or have docu-
mentation about why VTE prophylaxis is not given within 
24 hours of ICU admission, should be used as a perfor-
mance indicator.2 11 However, many clinicians perceive 
the risk of bleeding as more important than the risk of 
VTE, leading to a delay or even omission of VTE prophy-
laxis in a high proportion of patients.12–14 Observational 
studies have suggested that a delay of more than 1–3 days 
in initiating VTE prophylaxis is associated with a three-
fold increased risk of VTE and possibly also mortality in 
critically ill and injured patients.15–18 Early initiation of 
VTE prophylaxis using a multimodal approach, including 
the use of mechanical VTE prophylaxis for many critically 
ill and injured patients, may be the most effective way to 
reduce the disease burden of VTE in the critically ill and 
injured patients.19 20
Injury is a leading cause of death among young people 
and was responsible for two-thirds of deaths of young 
Australians in 2005 despite the injury death rate falling 
by 50% between 1986 and 2005.21 Guidelines from the 
American College of Chest Physicians have suggested that 
subcutaneous low-molecular-weight heparin (LMWH) 
or low-dose unfractionated heparin (UFH) should be 
used for thromboprophylaxis in patients at high risk of 
VTE including patients with major trauma.22 Although 
LMWH may be more efficacious than UFH, and there 
was no difference in major bleeding in patients without 
obvious contraindications to anticoagulants,23 the clinical 
concern about excessive haemorrhage persists especially 
for patients who have significant risk of bleeding after 
trauma. The incidence of asymptomatic PE between 3 
and 7 days after moderate to major trauma is extremely 
high (24%), despite LMWH or UFH prophylaxis,8 and 
use of pneumatic lower limb compression devices or UFH 
prophylaxis alone may not be completely effective in 
preventing VTE.8 22 24 Indeed, fatal PE is the third leading 
cause of death in patients who survive the first 24 hours 
after major trauma.25 As such, retrievable inferior vena 
cava (IVC) filters have been increasingly used in many 
patients with trauma.26 27
PrelImInary evIdence to suPPort the role of Ivc 
fIlters In major trauma
IVC filters are, however, expensive ($A>3000 per filter 
without considering radiology costs), invasive and asso-
ciated with significant complications, including erosion 
of the IVC, inducing thrombosis either above or below 
the filter, migration of the filter to the right atrium, and 
tilting or malpositioning of the filter resulting in inef-
fective filtering of emboli and fatal PE.28–30 Despite the 
risk of having significant complications and evidence to 
support its cost-effectiveness from randomised controlled 
trials (RCTs) or meta-analyses is sparse,31–35 IVC filters are 
increasingly used in many trauma centres worldwide.36 In 
2007, the US market for IVC filters was valued at under 
$200 million, with expected growth to top $300 million in 
2012.37 The most appropriate patients who will benefit 
from an IVC filter and the optimal time to insert and 
remove a retrievable IVC filter in patients after major 
trauma remains uncertain.38–40 Confounding these issues 
further, some retrievable IVC filters are not removed 
(>10% for many centres) which may induce long-term 
venous thromboembolic or mechanical complications 
especially if the filter is left in situ for longer than 60–90 
days.41 42
Currently the use of different strategies in preventing 
VTE after major trauma remains very controversial,22 43–50 
and the practice of thromboprophylaxis, especially in 
patients who have significant risk of bleeding within the 
first week of trauma, varies considerably between different 
trauma centres.25 The optimal method of thrombopro-
phylaxis in patients after major trauma at risk of bleeding 
remains highly uncertain.
Fatal PE is an important patient-centred outcome after 
major trauma.51 It has been reported to occur at a frequency 
between 0.4% and 4.2% after major trauma.24 52 53 It has 
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been argued that thromboprophylaxis may not be cost-ef-
fective in trauma patients,35 because fatal PE occurs more 
often in patients who have more severe traumatic injuries 
and some of these patients may die with PE, instead of 
from PE. Our recent study did, however, suggest that fatal 
PE is a preventable disease, with an attributable mortality 
of 50% (95% CI 36% to 62%), and it accounts for about 
12% of all deaths after major trauma.54 55 Furthermore, 
our recent multicentre observational studies showed that 
acute PE is a major cause of morbidity and mortality in 
critically ill patients,56 and omission of early VTE prophy-
laxis in critically ill patients, in particular after multiple 
trauma, either without clinical reasons (relative risk of 
1.66, 95% CI 1.22 to 2.25; absolute increase in risk 3.9%, 
95% CI 2.2 to 5.6) or due to contraindications from 
increased bleeding risk, is associated with a substantial 
increased risk of mortality.18
Retrievable IVC filters have been used in our patients 
with trauma in Western Australia (WA) since 2007, and in 
the years 2007 and 2008, 7.4% of all patients with trauma 
received a retrievable IVC filter. During these 2 years, 
the incidence of radiological or postmortem examina-
tion confirmed symptomatic PE occurred at 3% of all 
hospitalised patients with trauma, and this risk increased 
substantially to about 10% if only patients with trauma 
who had an Injury Severity Score (ISS) >15 (see online 
supplementary appendix 1) were considered. Since we 
noted that fatal PE is likely preventable with an IVC filter, 
retrievable IVC filters have been increasingly used as a 
primary thromboprophylaxis for our patients with trauma 
who have contraindications to pharmacological thrombo-
prophylaxis (>70–100 per annum in WA), very similar to 
many trauma centres.26 The preliminary findings from 
our most recent observational study showed that retriev-
able IVC filters appeared to be very effective in reducing 
fatal PE (none observed for all 223 patients who received 
an IVC filter). The use of IVC filters was still associated 
with substantial risks of lower or upper limb VTE (16%) 
and mechanical complications (12%) including adherent 
filter (5%) and IVC filter occlusion due to thrombus 
(4%), despite a high filter retrieval rate (87%) through 
a centralised protocol and process.42 Evidence suggested 
that if IVC filters are applied to all patients with major 
trauma, the estimated number of IVC filters needed to 
prevent one fatal PE is relatively large (mean 125, 95% CI 
100 to 167)54 and may not be cost-effective.
Because retrievable IVC filters are relatively expensive 
and invasive as a preventive strategy, it is more likely to 
be cost-effective if it is reserved for patients who have a 
very high risk of PE and, at the same time, the injuries are 
still compatible with survival when use of pharmacolog-
ical thromboprophylaxis is contraindicated.54 According 
to the Trauma Embolic Scoring System (TESS) (see 
online supplementary appendix 2),57 58 the TESS score 
for this type of patients would be likely greater than 10 
with an estimate risk of symptomatic VTE between 10% 
and 20% even when a proactive approach to detect VTE 
is not adopted. Even though many patients with major 
trauma will have deranged coagulation profiles which are 
considered as contraindicated to receive anticoagulant 
prophylaxis, their propensity to develop VTE does not 
appear to be different from those without such acquired 
coagulopathy.59–61 This group of patients with trauma will 
serve as the best candidates to assess the cost-effectiveness 
of IVC filters and will form the study population of this 
planned RCT in which we will adopt a proactive approach 
to detect VTE in our study patients (for details see below).
Primary aims of the study
1. To assess whether the early use of IVC filters as 
primary VTE prophylaxis can reduce the incidence 
of symptomatic PE in patients who are at high risk 
of developing DVT and PE after major trauma who 
also have contraindications to anticoagulant VTE 
prophylaxis.
2. To assess the cost-effectiveness of IVC filters in 
preventing PE after major trauma in this cohort of 
patients.
secondary aims of the study
1. To assess whether IVC filters are effective in reducing 
symptomatic PE in patients who do not receive 
pharmacological DVT prophylaxis within the first 7 
days of major trauma.
2. To assess the incidence of complications of IVC filters 
in patients with major trauma, including whether 
IVC filter will increase the risk of symptomatic and 
asymptomatic DVT in the lower limbs.
3. To assess the risk factors associated with DVT and PE 
after an IVC filter placement.
methods and analysIs
Protocol version 1.1 Feb 2015, no protocol amendment 
since initiation of the trial.
randomisation process
This is a pragmatic four-centre population-based phase IIb 
randomised controlled parallel-design study comparing 
the benefits, harms and cost-effectiveness of IVC filters 
in patients with major trauma at high risk of developing 
DVT and PE but with contraindications to pharmacolog-
ical VTE prophylaxis (see figure 1).
Written informed consent will be obtained either from 
each patient or their next of kin (or person responsible 
for the patient) for participation in the trial including 
use of long-term health outcome data through the data 
linkage unit; and for those who are allocated to the IVC 
filter group, separate clinical consents for IVC filter inser-
tion and removal will be obtained. Randomisation will be 
conducted by a random number generator, in permuted 
blocks stratified by centre, and allocation concealment 
will be maintained by a web-page randomisation and allo-
cation portal (http:// davinci. statisticalrevelations. com. 
au/). Blinding of the patients and attending clinicians 
is not intended or possible, but the data analyst will be 
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Figure 1 Flow chart showing inclusion and equal allocation of participants to receive an IVC filter or no IVC filter for 
thromboembolic prophylaxis. IVC, inferior vena cava; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin.
blinded to the study allocation. All VTE outcomes will be 
adjudicated by radiologists independent of the trial to 
reduce detection bias. Deidentified data will be entered 
into the password-protected web portal of the trial 
(http:// davinci. statisticalrevelations. com. au/); and only 
the chief investigators and members of the data moni-
toring and safety committee (DMSC) would have access 
to outcome data of the participants. As in May 2017, the 
trial has reached >80% enrolment target.
Inclusion criteria
Patients will be eligible for the trial (1) if they are consid-
ered to have contraindications to pharmacological 
thromboprophylaxis within 72 hours of hospital admis-
sion by their attending intensivist, trauma or spinal 
surgeon or neurosurgeon; and (2) ISS >15 (see online 
supplementary appendix 1). A list of contraindications to 
pharmacological VTE prophylaxis is described in the case 
record form (CRF) and web data portal.
exclusion criteria
1. severe head or systemic injury where death within 48–
72 hours is expected;
2. attending clinicians judge that patients are at 
low risk of bleeding, without contraindications 
to pharmacological VTE prophylaxis (as listed 
in the CRF) and can receive pharmacological 
thromboprophylaxis within 3 days after major trauma;
3. patients who have CT evidence of PE on admission to 
the hospital after trauma;
4. patients who have been treated with full systemic 
anticoagulation by warfarin, UFH or LMWH for pre-
existing medical disease (eg, patients with chronic 
atrial fibrillation requiring systemic anticoagulation) 
until admission due to trauma;
5. pregnancy;
6. aged <18 years old;
7. the IVC filter cannot be inserted within 72 hours of 
trauma admission.
study intervention and follow-up
In this study, the types of retrievable IVC filters used 
will be determined by the usual standard practice 
of the study centres, and will be inserted by a trained 
interventional radiologist either in the X-ray depart-
ment or ICU. Dates of insertion and removal of the IVC 
filter will be recorded. All IVC filters will be removed 
before hospital discharge or 90 days after the trauma, 
unless the clinicians believe that the IVC filter should 
be left for longer than this predefined period due to a 
strong clinical indication. The reasons for leaving the 
IVC filters will be recorded for those that are left in situ 
for >90 days. Currently, there is a WA statewide stan-
dardised protocol to ensure all retrievable IVC filters are 
removed by the Department of Radiology within 60–90 
days. All complications related to IVC filters will be 
recorded (eg, migration/displacement, caval occlusion) 
and managed according to the best clinical practice 
available. Mechanical complications related to the IVC 
filters are considered as severe adverse events (SAEs). All 
retrieved filters will be examined by the Department of 
Medical Engineering and Physics at Royal Perth Hospital 
for filter fractures, clot loads and mechanical properties 
(spring load of the ‘legs’, hardness of the alloy, chemical 
composition) as a substudy. All trauma deaths including 
those included in this study will be referred to the Coro-
ner’s office for postmortem examination to exclude 
fatal PE. Clinical follow-up will be maintained up to day 
90 after the injury (or hospital discharge whichever is 
longer) and subsequent further long-term follow-up will 
be achieved using data linkage of WA statewide health 
data for patients recruited in WA.
We adopt a proactive approach to detect asymptomatic 
DVT and symptomatic PE events in this study. Routine 
compression ultrasonography of the thighs and calf of all 
patients will be performed at 2 weeks after study enrol-
ment, or later if it is not possible at that time (eg, external 
fixation of lower limb fractures). Although routine lower 
limbs ultrasonography screening may reduce the risk of 
PE in seriously injured patients,62 it may not be cost-ef-
fective and is currently not used in the study centres nor 
most trauma centres in Australia.63
Imaging techniques used to diagnose PE and when this 
will be performed is at the discretion of the attending 
clinicians according to their clinical suspicion for PE. 
However, CT pulmonary angiography (CTPA) is consid-
ered mandatory if one or more of the following conditions 
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or situations occur unless a prior CTPA has already been 
performed within the last 3 days:
1. hypotension with systolic blood pressure <90 mm Hg 
for longer than 30 min;
2. unexplained chest pain;
3. hypoxia requiring ≥6 L/min of oxygen or 50% inspired 
oxygen to maintain arterial oxygen saturation >94%.
Routine imaging to screen for asymptomatic PE is not 
used in this study. Routine lower limb venography will not 
be used. D-dimers also will not be used to screen for DVT 
or PE in this study because of its very low specificity and 
positive predictive value in trauma patients.
concurrent treatments
The study is not blinded and attending clinicians should 
initiate pharmacological VTE prophylaxis as appropriate 
or as soon as possible. The trial recommends initiation 
of pharmacological VTE prophylaxis within 7 days of 
injury regardless of whether the patients have received 
an IVC filter. Because this is a pragmatic study, the deci-
sions about when to initiate UFH or LMWH and the 
doses needed after study enrolment are at the discretion 
of the attending clinicians and the data will be recorded. 
Intravenous low-dose heparin (<800 units/hour) as an 
anticoagulant for continuous renal replacement therapy 
is not contraindicated in the study, but patients who 
require full systemic anticoagulation by either UFH 
or LMWH before randomisation are not eligible for 
the study (eg, patients with atrial fibrillation requiring 
systemic anticoagulation). Antiplatelet agents for new 
or pre-existing medical conditions (eg, coronary artery 
disease, stroke, vertebral artery dissection) are permis-
sible.
All patients will receive mechanical DVT prophylaxis, 
in the form of lower limb compression devices, to the leg 
that is not injured. There is no restriction on attending 
clinicians to insert an IVC filter for VTE prophylaxis for 
patients randomised to the control group if there is a 
well-established indication to do so (eg, development of 
VTE with absolute contraindications to initiate systemic 
anticoagulation according to the treating clinicians) but 
these data will be recorded.
Primary endpoints
1. The composite endpoint of (A) PE as demonstrated 
by CTPA, high probability ventilation/perfusion scan, 
transoesophageal echocardiography (by showing 
clots within pulmonary arterial trunk), pulmonary 
angiography or postmortem examination during the 
same hospitalisation or 90-day after trauma whichever 
is earlier; and (B) hospital mortality.
2. The total cost of treatment including the costs of an 
IVC filter, total number of CT and ultrasound scans 
required, length of ICU and hospital stay, procedures 
and drugs required to treat PE or complications 
related to the IVC filter.
secondary endpoints
1. All complications related to an IVC filter, including 
displacement of the filter, erosion of IVC, inducing 
lower limb DVT and failure to remove the IVC filter 
in the recommended period.
2. Risk of fatal PE and non-fatal PE in patients who do 
not receive any pharmacological VTE prophylaxis 
within 7 days of major trauma.
3. Hospital mortality or 90-day mortality whichever is 
earlier.
4. Risk of bleeding after study enrolment
A. Major bleeding—contributing to death, at a 
critical site (eg, intracranial, spinal, epidural, 
airway haemorrhage), requiring transfusion (of 
either red blood cells, platelets or fresh frozen 
plasma) or a reduced haemoglobin >2 g/dL 
within 24 hours.
B. Non-major but clinically relevant bleeding—
requiring new medical interventions (eg, 
gastrointestinal endoscopy, local or systemic 
drugs to control bleeding).
C. Minor bleeding—not requiring new medical 
intervention (eg, mild haematuria, coffee-
ground nasogastric aspirate, skin bruises).
Participant withdrawal criteria and management
A. side effects of an IVC filter are detected and removal 
of the filter is deemed to confer more benefits 
than harms by the attending clinicians, but all 
complications related to the IVC filter and reasons 
for removal of the filter will be recorded and all 
patients will be followed up for at least 90 days 
after enrolment (or hospital discharge whichever is 
longer) and further follow-up on health outcomes 
is achieved by data linkage;
B. no participants withdrawing from the trial will be 
replaced and the proposed sample size has allowed 
for 20% dropout or crossover between the two 
treatment arms.
data collection (table 1)
The following data will also be obtained for all patients 
enrolled in the study and these characteristics will be 
used to generate a TESS to ensure that the randomisation 
is balanced, in terms of VTE risk, between the two groups 
(see online supplementary appendix 2).
1. demographics;
2. previous history of DVT/PE (see online 
supplementary appendix 3);
3. comorbidity including the history of smoking and 
drug use before the injury;
4. injury pattern and severity including ISS (see online 
supplementary appendix 1);
5. neurological signs and CT findings on admission 
for patients with head injury;
6. body mass index;
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7. medications before and after the injury: antiplatelet 
agents, hormonal replacement therapy or oral 
cntraceptive (OC) pills for female patients;
8. the duration between injury and hospital admission;
9. the duration between hospital admission and IVC 
filter insertion for patients who are randomised 
into IVC group and also for patients who require 
IVC filter in the control group due to clinical 
reason (ie, crossed over for clinical reason such 
as DVT but with active contraindication for 
anticoagulation);
10. total number of CTPA or other imaging modalities 
used (eg, echocardiography, ventilation / perfusion 
(V/Q) or perfusion scan, and so on);
11. the duration between hospital admission and the 
first attempt to diagnose PE by any form of imaging 
modality;
12. duration between hospital admission and the time 
to start the first dose of antithrombotic prophylaxis;
13. whether full anticoagulation is used, the indications 
for such therapy and the duration between hospital 
admission and full systemic anticoagulation;
14. whether UFH or LMWH is used for DVT/PE 
prophylaxis, the dose used, and duration between 
hospital admission and initiation of pharmacological 
thromboprophylaxis;
15. whether sequential lower limb compression device 
is used and the duration between hospital admission 
and the time this device is commenced and the total 
time of use of this type of device;
16. occurrence of DVT or PE and duration between 
hospital admission and occurrence of DVT/PE;
17. occurrence of acute kidney injury requiring renal 
replacement therapy;
18. use of femoral vein as an access for central venous 
catheter and dialysis catheter;
19. bleeding complications and interventions required 
for all bleeding complications after study enrolment 
as defined in the secondary endpoints;
20. ICU, hospital and 90-day mortality (if length of 
hospital stay is >90 days);
21. length of ICU and hospital stay: for patients with 
ICU readmission, the reasons for ICU readmission 
will be noted and the total number of ICU days of 
all ICU admission during the same hospitalisation 
will be calculated;
22. total length of mechanical ventilation, including 
invasive and non-invasive ventilation;
23. use of all forms of vasopressor/inotropic support 
and the total days of requiring such support after 
study enrolment;
24. use of intracranial pressure monitor;
25. the total number of operations required after 
study enrolment, reasons for the operations and 
the operative diagnoses; in addition, the number 
of surgical procedures that require cessation of 
heparin and the duration of withholding DVT 
prophylaxis each time will be recorded;
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Figure 2 Graph showing the power of the study in relation to the sample size in each study group and incidence of PE in the 
control group. PE, pulmonary embolism.
26. the type of the IVC filter used for the study patients 
and dates of insertion and removal of the IVC filter; 
for IVC filters that are left in situ for >90 days, the 
reasons for leaving the IVC filters will be recorded;
27. proportion of IVC filters found to have clots after 
being retrieved;
28. all complications related to IVC filters (eg, migration/
displacement, caval occlusion); mechanical 
complications related to the IVC filters are 
considered as SAEs;
29. we will also use the unique data linkage unit in 
WA to evaluate hospital readmissions due to all 
causes, VTE, complications related to the IVC filters 
and long-term survival at about 3–5 years after 
study enrolment as a substudy of this randomised 
controlled study.
sample size calculation
Although IVC filters are increasingly used for thrombo-
prophylaxis in many patients with trauma, their clinical 
effectiveness has never been well documented. They are 
invasive, expensive and have significant complications 
some of which are life threatening. It is important to 
demonstrate clinical superiority before they are widely 
used in patients who are already at risk of mortality and, 
hence, a superiority trial rather than a non-inferiority 
trial is preferred. We are planning a study of independent 
treatment cases and placebo controls with one control 
per case. The incidence of asymptomatic PE between 3 
and 7 days after moderate to major trauma is extremely 
high (24%) despite LMWH or UFH prophylaxis. Prior 
data indicate that the PE rate among patients who are at 
high risk of VTE without thromboprophylaxis (similar to 
our control patients) is >0.09 (or 9%). The relatively high 
incidence of PE is expected because (A) we use a proac-
tive approach to detect mildly symptomatic PE, and (B) 
we have chosen the group of patients with trauma who 
are at extreme risk of VTE and, at the same time, cannot 
receive pharmacological thromboprophylaxis. The TESS 
score of these patients is expected to be >10. Evidence 
suggested that IVC filters are highly effective in reducing 
PE. If the PE rate of the intervention group is close to 
0.5%, we will need to study 97 experimental subjects and 
97 control subjects to be able to reject the null hypothesis 
that the failure rates for experimental and control subjects 
are equal with probability (power) 0.8 (or 0.9 if the base-
line risk of PE is 10%). We assume there will be a small 
proportion of patients who will have study intervention 
crossed over between the two groups. Therefore, the total 
sample size of this study is 240 (120 per group), allowing 
up to 20% of the study subject crossed over between the 
control and intervention groups without affecting the 
power of the study (see figure 2). If an IVC is associated 
with an increased risk of lower limb DVT, this sample size 
will also have >80% power to detect an increased risk of 
DVT due to the IVC filter from 10% to 25%.
data analysis plan
An interim analysis is not planned because this will 
compromise the power of the proposed study. However, 
fatal PE and SAEs will be reported to the ethics committee 
and monitored by an independent DMSC comprising 
two members who have experience in conducting clinical 
trials related to trauma and critical illness. Statistically, at 
least four fatal PEs all occurring only in the control group 
of 100–120 patients are needed to conclude that without 
IVC (or control group) would lead to an increased risk 
of fatal PE in the study population and this will termi-
nate the entire trial before the completion of the study 
with the proposed sample size (n=240). Any significant 
side effects experienced by participants of the trial will be 
addressed according to the standard clinical management 
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procedures that this may include early removal of the IVC 
filter. The primary and secondary outcomes will be anal-
ysed by an intention-to-treat principle, and as such, any 
patients that cross over into the other group will be anal-
ysed as the group they are originally allocated to.
Categorical and continuous baseline variables and 
outcomes with skewed distributions will be compared 
by χ2 test  and Mann-Whitney U test, respectively. Kaplan-
Meier survival analysis will be used to assess whether early 
use of retrievable IVC filters will affect the time for the 
patients to experience the first composite endpoint event 
(eg, PE or death) within 90 days of randomisation. A 
predefined restricted or subgroup analysis on risk of fatal 
PE and non-fatal PE in patients who do not receive any 
pharmacological VTE prophylaxis within 7 days of major 
trauma is planned.
As for the economic analysis, it will comprise (A) the 
net resource cost of IVC compared with the status quo 
without IVC (cost analysis) and (B) comparison of net 
resource use with net health benefits (cost-effectiveness).
A. Cost analysis
The total cost of treatment using an IVC filter includes 
the device itself, the consumables required for insertion 
and removal, the costs of personnel required for the 
procedure and costs of complications. Cost components 
for both arms of the trial which require analysis include 
length of index hospital stay including number of days 
in ICU, readmission days including ICU, pharmaceuticals 
required to treat PE, DVT prophylaxis, associated investi-
gations including all X-rays, CTPA, ultrasonography and 
any other associated procedures. Follow-up will extend 
to 90 days postprocedure in the first instance; further-
more, long-term outcomes including survival and venous 
thromboembolic complications and the cost-effectiveness 
in preventing these complications beyond day 90 will be 
assessed through use of linked health data. Costs will be 
drawn from hospital finance data where possible, but all 
resources will be collected in standard units and otherwise 
quantified using standard Australian resource data such 
as the Medicare Benefits Schedule (MBS) for medical 
procedures and the Pharmaceutical Benefits Scheme 
(PBS) for pharmaceuticals. Costs will be standardised 
to 2015 Australian dollars. The cost analysis will take 
the perspective of the Australian health system. Because 
different institutions may have ways of managing patients 
with trauma and hence also the costs needed, we will also 
analyse the cost outcomes using the funding provided to 
each recruited patient according to the Australian Activi-
ty-Based Funding model.
Current cost data estimates
It is estimated that the total cost of the procedure using 
IVF filters is approximately $A6000, comprising: $3000—
IVF filter, $3000—consumables for insertion + labour 
costs for insertion and removal.64 Given the signifi-
cant number needed to treat (estimated to be 10), net 
savings are unlikely to accrue unless additional individual 
benefits are evident such as survival and venous insuffi-
ciency after VTE. Given estimates of 20% expected DVT 
and 9%–10% expected PE in the study cohort, the device 
will only be cost saving if PE costs on average, more than 
$A60 000. However, if there is a difference in life saved 
after the use of IVC filters—that is a reduction in fatal PE 
as suggested by existing observational studies35—this will 
contribute enormously to cost-effectiveness (as distinct 
from cost savings).
B. Cost-effectiveness
Costs of the procedure will be compared with health 
outcomes as determined from the trial. The cost anal-
ysis as described above will indicate whether IVC filters 
provide a net saving to the healthcare system. A net saving 
in costs combined with a net health benefit suggests a 
dominant health intervention strategy. In the event that 
the IVC filters demonstrate health benefits at some cost, 
formal cost-effectiveness analysis can provide informa-
tion around the relative health benefits for a given cost, 
compared with alternative resource demands, such as 
comparable procedures.
Using mortality outcomes, both at 90 days after admis-
sion and long term after hospital discharge obtained by 
linked health data, cost per life year gained can be esti-
mated. Long-term outcomes can also be estimated using 
Markov decision analysis based on probabilities from the 
literature. Sensitivity analysis will be undertaken to test 
robustness of the parameters, to identify cost drivers and 
to estimate conditions under which the procedure is 
cost-effective. Cost-effectiveness ratios can be compared 
with similar procedures to estimate potential acceptability 
for wider policy.
ethIcs and dIssemInatIon
This study has been approved by the ethics committees 
of the Coroner’s Court of Western Australia (EC03-14), 
Royal Perth Hospital (14-139; consent forms in online 
supplementary appendix 4), Sir Charles Gairdner 
Hospital (2014-161), Fiona Stanley Hospital (14-139) and 
Royal Brisbane and Women’s Hospital (15/QRBW/437). 
Informed consent information forms can be obtained 
by contacting the corresponding author of this manu-
script (KMH). This study has been registered with the 
Australian and New Zealand Clinical Trial Register 
(ACTRN12614000963628). A manuscript with the results 
of the primary clinical outcome and secondary outcomes 
will be published in a peer-reviewed journal. Separate 
manuscripts will be written on cost-effective analyses, 
determinants of the mechanical complications of the IVC 
filters and long-term outcomes after use of retrievable 
IVC filters, and these will also be submitted for publica-
tion in peer-reviewed journals. Chief investigators listed 
in this study protocol and those who contribute to the 
completion of the trial including drafting and critical 
revising of the final manuscripts will be the authors of the 
published manuscripts. Patient-level raw data of this study 
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can be obtained from the corresponding author and 
the full data set may also be deposited in open clinical 
data registry if funding is available on completion of all 
substudies.
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